66P Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
Titel:
66P Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
Auteur:
Wang, X. Ma, J. Zhang, J. Yang, Y. Zheng, D. Liang, H. Zhang, L. Xin, Y. Ling, X. Fang, C. Jiang, H. Zheng, W.